CONMED Corp CNMD
Last close
49.32
2026-09-04
Market cap
$1.48B
2026-06-30 share count
52-week range
31.44 - 54.80
Valuation FY2025 figures against the last close
P/S1.1x
P/E32.7x
P/FCF9.8x
EV/EBITDA12.3x
Dividend yield1.7%
Diluted EPS1.51
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.37B | $1.31B | $1.24B | $1.05B | $1.01B | $862.5M | $955.1M | $859.6M | $796.4M | $763.5M |
| Cost of revenue | $624.2M | $574.0M | $568.5M | $474.2M | $442.6M | $402.2M | $430.4M | $390.5M | $365.4M | $355.2M |
| Gross profit | $750.5M | $733.0M | $676.2M | $571.2M | $568.0M | $460.3M | $524.7M | $469.1M | $431.0M | $408.3M |
| R&D | $55.9M | $54.4M | $52.6M | $47.2M | $43.6M | $40.5M | $45.5M | $42.2M | $32.3M | $32.3M |
| SG&A | $592.0M | $478.3M | $503.0M | $454.0M | $414.8M | $373.8M | $400.1M | $355.6M | $351.8M | $338.4M |
| Total operating expenses | $647.9M | $532.7M | $555.6M | $501.2M | $458.3M | $414.3M | $445.6M | $397.8M | $384.1M | $370.7M |
| Operating income | $102.6M | $200.3M | $120.6M | $70.1M | $109.7M | $46.0M | $79.1M | $71.3M | $46.9M | $37.7M |
| Interest expense | $31.1M | $37.3M | $39.8M | $28.9M | $35.5M | $44.1M | $42.7M | $20.7M | $18.2M | $15.4M |
| Pre-tax income | $71.1M | $163.0M | $80.8M | -$70.9M | $73.1M | $1.6M | $31.2M | $50.7M | $28.7M | $19.4M |
| Income tax | $24.1M | $30.6M | $16.4M | $9.7M | $10.6M | $7.9M | $2.6M | $9.8M | $26.8M | $4.7M |
| Net income | $47.1M | $132.4M | $64.5M | -$80.6M | $62.5M | $9.5M | $28.6M | $40.9M | $55.5M | $14.7M |
| EPS, basic | 1.52 | 4.29 | 2.10 | -2.68 | 2.14 | 0.33 | 1.01 | 1.45 | 1.99 | 0.53 |
| EPS, diluted | 1.51 | 4.25 | 2.04 | -2.68 | 1.94 | 0.32 | 0.97 | 1.41 | 1.97 | 0.52 |
| Shares, diluted (wtd. avg.) | $31.1M | $31.1M | $31.5M | $30.0M | $32.2M | $29.5M | $29.5M | $28.9M | $28.2M | $28.0M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $40.8M | $24.5M | $24.3M | $28.9M | $20.8M | $27.4M | $25.9M | $17.5M | $32.6M | $27.4M |
| Receivables | $247.8M | $237.7M | $242.3M | $191.3M | $183.9M | $177.2M | $189.1M | $181.6M | $167.0M | $148.2M |
| Inventory | $355.5M | $346.7M | $318.3M | $332.3M | $231.6M | $194.9M | $164.6M | $154.6M | $141.4M | $135.9M |
| Total current assets | $672.9M | $640.0M | $615.6M | $581.2M | $460.1M | $416.7M | $397.4M | $374.4M | $356.8M | $330.5M |
| Property, plant and equipment | $113.3M | $115.8M | $120.7M | $115.6M | $108.9M | $111.4M | $118.9M | $113.2M | $116.2M | $122.0M |
| Goodwill | $807.0M | $805.4M | $806.8M | $815.4M | $617.5M | $618.4M | $618.0M | $400.4M | $402.0M | $397.7M |
| Other intangibles | $582.1M | $617.7M | $649.5M | $681.8M | $471.0M | $501.5M | $532.8M | $413.2M | $414.9M | $419.5M |
| Total assets | $2.33B | $2.31B | $2.30B | $2.30B | $1.77B | $1.75B | $1.78B | $1.37B | $1.36B | $1.33B |
| Accounts payable | $93.6M | $102.2M | $88.2M | $73.4M | $58.2M | $53.3M | $56.0M | $53.5M | $42.0M | $41.6M |
| Short-term debt | — | — | — | — | — | — | — | $18.3M | $14.7M | $10.2M |
| Total current liabilities | $315.0M | $278.1M | $310.7M | $296.6M | $196.6M | $190.2M | $188.1M | $160.9M | $150.0M | $114.0M |
| Long-term debt | — | — | — | — | — | — | — | $438.6M | $471.7M | $488.3M |
| Total liabilities | $1.29B | $1.34B | $1.47B | $1.55B | $980.6M | $1.04B | $1.06B | $706.9M | $726.5M | $748.4M |
| Retained earnings | $588.8M | $560.3M | $452.5M | $412.6M | $496.6M | $457.4M | $470.8M | $464.9M | $440.1M | $406.9M |
| Total equity | $1.03B | $962.7M | $834.2M | $745.5M | $785.4M | $709.0M | $710.5M | $662.3M | $631.4M | $580.6M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $170.7M | $167.0M | $125.3M | $33.4M | $111.8M | $64.5M | $95.1M | $74.7M | $65.6M | $39.9M |
| Depreciation and amortisation | $17.1M | $16.6M | $16.2M | $16.1M | $16.5M | $18.0M | $18.7M | $18.5M | $20.1M | $20.5M |
| Stock-based compensation | $28.3M | $25.6M | $24.3M | $21.7M | $16.3M | $13.1M | $11.8M | $10.0M | $8.5M | $8.4M |
| Capital expenditure | $19.8M | $13.1M | $19.0M | $21.8M | $14.9M | $13.0M | $20.1M | $16.5M | $12.8M | $14.8M |
| Investing cash flow | -$21.0M | -$13.1M | -$20.0M | -$249.5M | -$14.9M | -$13.6M | -$387.7M | -$16.5M | -$29.1M | -$266.0M |
| Financing cash flow | -$135.8M | -$151.0M | -$110.4M | $225.0M | -$101.5M | -$52.1M | $300.9M | -$72.3M | -$34.9M | $182.5M |
| Dividends paid | $24.7M | $24.7M | $24.5M | $24.0M | $23.3M | $22.8M | $22.6M | $22.4M | $22.3M | $22.2M |
| Buybacks | — | — | — | — | — | — | — | — | — | $0 |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0000816956-26-000047.
Others in SIC 3845
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| MDT | Medtronic plc | $120.46B | 25.2x | 8.4% |
| LIVN | LivaNova PLC | $4.51B | — | 10.7% |
| ITGR | Integer Holdings Corp | $4.30B | 43.8x | 8.0% |
| TMDX | TransMedics Group, Inc. | $3.12B | 18.5x | 37.1% |
| AXGN | Axogen, Inc. | $2.60B | — | 20.2% |
| BLFS | BIOLIFE SOLUTIONS INC | $1.72B | — | 28.9% |
| CBLL | Ceribell, Inc. | $948.7M | — | 36.1% |
| CV | CapsoVision, Inc | $299.8M | — | 15.3% |